Vorapaxar.
Merck & Co. is developing vorapaxar (SCH 530348), a thrombin receptor antagonist, for the prevention and treatment of arterial thrombosis. Vorapaxar is currently being evaluated in two large-scale multinational phase III trials (TRA*CER and TRA 2°P-TIMI 50) for the treatment and prevention of cardiac events in almost 30,000 patients with acute coronary syndromes and those with prior myocardial infarction or stroke, as well as patients with acute coronary syndrome and those with peripheral arterial disease. This review discusses the development history and scientific profile of this new compound.